We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pfizer Seeks More BE Requirements for Generics of Its Opioid Embeda
Pfizer Seeks More BE Requirements for Generics of Its Opioid Embeda
January 15, 2013
Pfizer is asking the FDA to add five additional bioequivalence (BE) recommendations for ANDA applicants referencing its pain drug Embeda.